Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07654426 | The CARDIOPROTECT Trial | recruiting | Phase 2 | 60 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07729397 | Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)(ANCILE-30) | not yet recruiting | Phase 1 | 21 | The Methodist Hospital Research InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03478514 | Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma | active not recruiting | Phase 2 | 39 | Alliance Foundation Trials, LLC.OTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04333524 | FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role(PIMENTO) | active not recruiting | — | 496 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 3 | Jul 24, 2026 | clinicaltrials |
| NCT05725720 | Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy(MicroCar) | active not recruiting | — | 69 | University of BolognaOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05926765 | A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia(AQUAx2) | active not recruiting | Phase 2 | 290 | MeiraGTx, LLCINDUSTRY | 3 | Jul 24, 2026 | clinicaltrials |
| NCT07121946 | This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma | recruiting | Phase 1 | 42 | LTZ Therapeutics, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07725406 | Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma(Prime REMIX) | not yet recruiting | Phase 1 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04212013 | A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma | active not recruiting | Phase 3 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07082686 | A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) | recruiting | Phase 2 | 75 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT01479842 | Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 | 48 | Kami Maddocks, MDOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04404283 | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL(ECHELON-3) | active not recruiting | Phase 3 | 239 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 14 | Jul 22, 2026 | clinicaltrials |
| NCT05735834 | Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients(RITZ) | active not recruiting | Phase 3 | 122 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 8 | Jul 22, 2026 | clinicaltrials |
| NCT06765317 | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07494565 | Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL | recruiting | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07719556 | Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) | recruiting | Phase 2 | 39 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07719855 | A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma | not yet recruiting | Phase 3 | 652 | Ruijin HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05821088 | Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | active not recruiting | Phase 2 | 37 | David Bond, MDOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06471738 | Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | recruiting | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06863402 | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype | recruiting | Phase 2 | 32 | Roswell Park Cancer InstituteOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07713459 | A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | not yet recruiting | Phase 2 | 105 | Kure Cells, INCINDUSTRY | 0 | Jul 20, 2026 | clinicaltrials |
| NCT07714421 | Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients | not yet recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04783415 | Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | active not recruiting | Phase 2 | 12 | City of Hope Medical CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05052528 | Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 36 | University of California, DavisOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07711327 | Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy | not yet recruiting | — | 500 | Tina BaykanerOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03282396 | Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma | active not recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06364423 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709624 | Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study | active not recruiting | — | 50 | TTY BiopharmINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01371630 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 276 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02494700 | Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705308 | A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma | not yet recruiting | Phase 2 | 140 | Ruijin HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705386 | Development of an AI-Assisted Diagnostic Tool for Mycosis Fungoides and Other Cutaneous Lymphoproliferative Diseases Using Microscopic Image Analysis: A Training and Validation Study | active not recruiting | — | 463 | Cairo UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02717624 | A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL | active not recruiting | Phase 1 | 72 | Acerta Pharma BVINDUSTRY | 3 | Jul 14, 2026 | clinicaltrials |
| NCT05371808 | Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: | recruiting | — | 247 | Canadian Cancer Trials GroupNETWORK | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07702851 | A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP | not yet recruiting | Phase 2 | 47 | Yonsei UniversityOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT03774654 | CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | active not recruiting | Phase 1 | 13 | Baylor College of MedicineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | recruiting | Phase 2 | 315 | Miltenyi Biomedicine GmbHINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT06043011 | Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms(RUBIN) | recruiting | — | 2,950 | iOMEDICO AGINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07599423 | A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 96 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment | not yet recruiting | Phase 2 | 138 | SWOG Cancer Research NetworkNETWORK | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07697339 | HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma | not yet recruiting | Phase 1 | 40 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jul 13, 2026 | clinicaltrials |
| NCT04419519 | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | active not recruiting | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04712097 | A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma(Celestimo) | active not recruiting | Phase 3 | 478 | Hoffmann-La RocheINDUSTRY | 15 | Jul 10, 2026 | clinicaltrials |
| NCT05077527 | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 20 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05665062 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | active not recruiting | Phase 1 | 36 | SynthekineINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05672251 | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06558604 | Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma(GLOASIS) | recruiting | Phase 2 | 100 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05098613 | Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients | recruiting | Phase 1 | 68 | University of Colorado, DenverOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06015880 | Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06300528 | Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas | active not recruiting | Phase 2 | 1 | University of UtahOTHER | 1 | Jul 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 27, 2026source: clinicaltrials